Incyte(INCY) - 2024 Q2 - Quarterly Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $1,044 million in the second quarter (Q2'24) (+9% Y/Y) – Jakafi (ruxolitinib) net product revenues of $706 million in Q2'24 (+3% Y/Y), total patients increased +7% Y/Y; raising the bottom end of full year 2024 guidance to a new range of $2,710 - $2,750 million ® – Opzelura (ruxolitinib) net product revenues of $122 million in Q2'24 (+52% Y/Y); continued up ...